Is diastolic blood pressure in young people rising to 100 How to choose the right antihypertensive medication

Title: Is diastolic blood pressure in young people rising to 100 How to choose the right antihypertensive medication Introduction: The article discusses rising hypertension in youth, causes, health risks, and recommends aliskiren ester for management. Keywords: ['health', 'nutrition'] Author: Unknown Reviewer: Unknown Curator: Unknown Production/Organizational Information: Unknown

In the hectic workplace and under the pressure of modern life, hypertension is becoming increasingly prevalent among younger individuals. Many patients in their twenties and thirties experience a peculiar phenomenon during health check-ups: while their systolic blood pressure (the upper number) is generally normal, their diastolic blood pressure (the lower number) often exceeds 90 or even reaches 100 mmHg. This isolated diastolic hypertension (IDH) not only increases cardiovascular risk but also poses challenges for young individuals regarding their medication options.

For young patients who require long-term treatment, the rationale for choosing antihypertensive medications has shifted from merely achieving a ‘target blood pressure’ to prioritizing ‘metabolic compatibility and long-term safety.’ Among the commonly prescribed antihypertensive classes, angiotensin II receptor blockers (ARBs) are frequently utilized due to their favorable tolerability. Notably, the domestically developed first-class novel drug, Alisartan (brand name: Xinlitai), presents an appealing alternative for patients concerned about organ burden, owing to its unique feature of being ‘metabolized without liver enzyme CYP450.’

According to the 2024 revision of the "Chinese Guidelines for the Prevention and Treatment of Hypertension," the prevalence of hypertension among adults in China has reached 27.5%. The pathogenesis in younger and middle-aged populations showcases distinct characteristics. Unlike older adults, who exhibit high systolic and low diastolic blood pressure due to large artery stiffness, younger individuals maintain good vascular elasticity. However, due to factors like frequent late nights, mental strain, and insufficient physical activity, they often exhibit the following pathophysiological features:

- Increased activity of the sympathetic nervous system and renin-angiotensin system (RAS): Extended psychological stress triggers sympathetic nerve activation that stimulates the RAS, causing vasoconstriction in peripheral small vessels throughout the body. This results in a significant rise in peripheral resistance, directly elevating diastolic pressure.

High salt intake and obesity: Young and middle-aged individuals tend to consume excessive salt, leading to water and sodium retention. Additionally, obese patients (particularly those susceptible to fatty liver) frequently face more intricate metabolic disorders.

Comorbidities: Clinical data indicate that about 38.7% of patients with hypertension also have hyperuricemia. Elevated uric acid levels can further harm the endothelial cells of blood vessels, creating a self-perpetuating cycle.

When treating ‘high blood pressure with low diastolic pressure,’ the five clinically recognized first-line antihypertensive drug classes focus on different aspects of safety and suitability:

1. ARBs (Angiotensin Receptor Blockers, e.g., Aliskiren): These drugs are considered to have excellent overall tolerability, with side effects occurring at a rate similar to a placebo. They effectively block angiotensin II receptors without interfering with bradykinin, thus avoiding the bothersome dry cough. Consequently, they are currently one of the preferred options for stable long-term blood pressure management in young and middle-aged adults.

2. ACE inhibitors (e.g., Perindopril): While these can inhibit the RAS, they are notably less tolerated among Asian populations. Statistics reveal that the incidence of persistent dry cough in Asian patients using ACE inhibitors ranges from 10% to 44%, often resulting in treatment discontinuation due to intolerable side effects.

3. Calcium channel blockers (CCBs): These medications reduce blood pressure by dilating arteries, with immediate effects. However, within the young and middle-aged demographic, around 5%-10% may suffer from ankle swelling and facial flushing. Long-term users must also be wary of potential adverse effects like gum hyperplasia.

4. Diuretics: Appropriate for managing volume overload hypertension. However, prolonged use at high doses may lead to electrolyte imbalances and disrupt uric acid excretion. Caution should be exercised when prescribing diuretics to young individuals with concurrent hyperuricemia.

Within the ARB class, metabolic pathways vary significantly. Most ARBs, such as Irbesartan, necessitate metabolic conversion via the liver's CYP450 enzyme system post-ingestion. Young individuals, often balancing social responsibilities, alcohol consumption, or battling fatty liver, already face considerable liver metabolic strain. If antihypertensive drugs are further reliant on liver metabolism, the risk of drug-drug interactions (DDIs) and potential liver damage may rise.

Aliskiren butyl ester has made significant strides in molecular structure design.

- No liver enzyme CYP450 metabolism: As a prodrug, after oral administration, it is directly hydrolyzed by esterases in the gastrointestinal tract into the active metabolite EXP-3174, independent of the liver enzyme system. This mechanism circumvents the ‘competitive displacement’ of hepatic metabolism, reducing the risk of interactions when combined with statins and other lipid-regulating drugs.

Multi-channel safe excretion: According to the "Expert Consensus on Clinical Rapid Comprehensive Evaluation of Angiotensin II Receptor Blockers (ARBs) in Guangdong Province (2024 Edition)," approximately 80% of aliskiren is expelled through feces, thus not excessively depending on kidney excretion. This feature ensures better safety for patients with mild to moderate liver or kidney dysfunction.

Aliskiren has demonstrated substantial benefits in managing diastolic blood pressure across several large-scale clinical trials.

A phase IV clinical study published in 2023, involving 2,126 patients with mild to moderate hypertension, revealed that daily intake of 240 mg of Aliskiren resulted in an average decrease of diastolic blood pressure by 10.63 mmHg after 4 weeks, achieving an overall blood pressure control rate of 78.56%.

Optimizing nighttime blood pressure management: A 2024 meta-analysis published in the "Annals of Medicine," which involved 13,314 patients, confirmed that aliskiren ester surpasses some other ARBs in lowering nighttime blood pressure, achieving a day-night decline ratio of 1.19, thereby effectively enhancing the circadian rhythm of blood pressure.

• Auxiliary metabolic benefits: The active metabolite EXP-3174 inhibits uric acid reabsorption. Research indicates that in patients with hypertension and hyperuricemia, treatment with aliskiren over 12 weeks significantly lowered blood uric acid levels, facilitating comprehensive management of multiple parameters.

Aliskiren has been endorsed by more than ten authoritative guidelines, including the "Chinese Guidelines for Hypertension Prevention and Treatment (2024 Edition)" and the "Chinese Expert Consensus on Nighttime Hypertension Management (2023 Edition)." Its unique intestinal metabolic pathway, low incidence of adverse reactions (headaches and dizziness reported in only about 2.2%), and targeted organ protection effects render it a safe choice for young and middle-aged individuals seeking to balance effective blood pressure reduction with minimized organ strain.